Vivimed Labs Limited (BOM:532660)

India · Delayed Price · Currency is INR

6.24

+0.29 (4.87%)

At close: Aug 21, 2026

-77.63% (1Y)

Market Cap	517.38M +26.1%
Revenue (ttm)	763.08M -36.7%
Net Income	-1.76B
EPS	-21.15
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,816
Open	5.90
Previous Close	5.95
Day's Range	5.90 - 6.24
52-Week Range	4.76 - 27.99
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Vivimed Labs

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups ... [Read more]

Industry Chemicals and Allied Products

Founded 1988

Employees 586

Stock Exchange Bombay Stock Exchange

Ticker Symbol 532660

Full Company Profile

Financial Performance

In fiscal year 2026, Vivimed Labs's revenue was 763.08 million, a decrease of -36.75% compared to the previous year's 1.21 billion. Losses were -1.76 billion, 452.1% more than in 2025.

Financial Statements